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Abstract Pain is one of the most frequent and most
distressing symptoms in the course of cancer. The man-
agement of pain in cancer patients is based on the
concept of the World Health Organization (WHO) anal-
gesic ladder and was recently updated with the EAPC
(European Association for Palliative Care) recommenda-
tions. Cancer pain may be relieved effectively with
opioids administered alone or in combination with ad-
juvant analgesics. Corticosteroids are commonly used
adjuvant analgesics and play an important role in neu-
ropathic and bone pain treatment. However, in spite of
the common use of corticosteroids, there is limited
scientific evidence demonstrating their efficacy in cancer
patients with pain. The use of corticosteroids in spinal
cord compression, superior vena cava obstruction, raised
intracranial pressure, and bowel obstruction is better
established than in other nonspecific indications. This
review aims to present the role of steroids in pain and
management of other symptoms in cancer patients
according to the available data, and discusses practical
aspects of steroid use.
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Introduction
Pain is a vital problem in cancer as it occurs in 30–50 %
patients in earlier stages and in 70–90 % of these patients
with advanced disease. The management of this symptom is
generally based on the concept of the World Health Orga-
nization (WHO) analgesic ladder. This three-step framework
was published for the first time in 1986 by the WHO to
promote rational use of analgesic medications in the treat-
ment of cancer pain. Step I recommends nonopioid analge-
sics for mild pain. Step II specifies the use of weak opioids
for moderate pain. Step III comprises the use of strong
opioids for severe pain [1]. Recent cancer pain management
guidelines in Europe are based on European Association for
Palliative Care (EAPC) recommendations [2, 3••]. The
knowledge of both basic types of pain (nociceptive and
neuropathic) and their responsiveness to opioids is neces-
sary to achieve good pain alleviation. Medical data demon-
strate that complete pain relief is rarely achieved in cancer
patients; nonetheless, it can be significantly reduced [4].
To achieve better pain relief, apart from the use of the
analgesics recommended by the WHO ladder, an appropriate
application of adjuvant analgesics (i.e., for neuropathic pain),
supportive drugs (for the prevention and treatment of opioid
adverse effects) [5], and nonpharmacological measures such
as radiotherapy and invasive procedures (nerve blockades and
neurolytic blocks) [6] should be considered and applied. Cer-
tain data confirm some of the generally known rules, which
are presented below. In patients with bone pain, opioids may
be combined with nonsteroidal anti-inflammatory drugs
(NSAIDs) and bisphosphonates along with local or systemic
radiotherapy [7]. Neuropathic pain apart from opioid analge-
sics may require antidepressants, anticonvulsants, and local
anesthetics. In patients with very severe neuropathic pain, the
combination of opioids and N-methyl-D-aspartate receptor
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(NMDA) antagonists, namely ketamine, is recommended [8].
Patients with visceral, colicky pain, especially in the course of
bowel obstruction, should be treated with opioid analgesics
and spasmolytics such as hyoscine butylbromide, hyoscine
hydrobromide, or glycopyrrolate [9].
Steroids can reduce pain intensity by inhibiting prosta-
glandin synthesis and reducing vascular permeability. Their
role in controlling cancer pain and other indications in the
course of cancer and some practical aspects of steroid use
will be discussed in this article. According to the WHO and
EAPC pain management recommendations, an adjuvant
pain medication should be considered at each step of the
WHO analgesic ladder, especially when the anti-
inflammatory effect is needed.
Steroid Classification and Clinical Consequences
Endogenous steroids, depending on their nature, site of
synthesis, and specific clinical features, can be divided into
four groups: corticosteroids (glucocorticosteroids and min-
eralocorticosteroids), progestogens, androgens, and estro-
gens. Generally, steroids are produced in the adrenals and
gonads, and some other tissues such as the bowel, liver,
prostate, and nervous system (neurosteroids) may synthesize
or metabolize them [10]. Corticosteroids have a wide range
of actions. The principal sites of action and clinical conse-
quences of corticosteroid excess are presented in Table 1.
The knowledge of different corticosteroid properties is an
important factor in the therapeutic decision making process.
Table 2 compares the most often used glucocorticosteroids
with respect to the anti-inflammatory properties and the
potency of sodium retention and the hypothalamic-
pituitary-adrenal (HPA) axis suppression.
The anti-inflammatory effect and vascular permeability
reduction are the clinical results of steroid use. Because the
mineralocorticoid properties of steroids may lead to a higher
risk of sodium excess, potassium loss, and water retention
(in such cases, a concurrent supplementation of potassium
should be considered), cortisone or hydrocortisone are rare-
ly employed for long-term anti-inflammatory therapy (due
to the highest sodium-retaining potency). The negative feed-
back of the HPA axis by endogenous and synthetic steroids
is well established. It is a dose- and time-dependent process.
Consequently, a sudden cessation of corticosteroid therapy
may result in adrenal failure. Clinically significant HPA axis
suppression is rare if a steroid is administered for less than
3 weeks. Such patients can withdraw from steroids sudden-
ly, with no harmful effects [11]. There are some clinical
situations (i.e., myopathy or dysphagia) when steroids have
to be discontinued even if they have been used much longer.
Various syndromes may occur when the glucocorticoid is
withdrawn or reduced. The first is relapse of the disease for
which the steroids were prescribed. The second is a combina-
tion of nonspecific symptoms of steroid withdrawal syndrome
(i.e., lethargy, depression, anorexia, nausea, myalgia, or ar-
thralgia). This syndrome must be distinguished from the sup-
pressed HPA axis or relapse of the underlying disease. The
third syndrome is acute adrenal insufficiency, which could be
precipitated by surgery, intercurrent disease, or stress and may
result in a hemodynamic collapse [12]. Clinicians are often
unsure how to safely reduce the dose of steroids. The most
suitable method of tapering has not been established as yet.
Table 1 The principal sites of action of glucocorticoids in humans and
some clinical consequences of its excess
Site of action Consequences of glucocorticoid excess





↓LH, FSH, TSH release, ↓GH secretion
Gastrointestinal
tract







Promotes visceral obesity (cushingoid appearance)
Cardiovascular/
renal





Protein catabolism/collagen breakdown, skin
thinning, muscular atrophy (myopathy), impaired











CNS central nervous system, LH luteinizing hormone, FSH follicle-
stimulating hormone, TSH thyroid-stimulating hormone, GH growth
hormone
(Adapted and modified from Stewart [11])








Cortisol 1 1 1
Prednisolone 0.75 3 4
Methylprednisolone 0.5 6.2 4
Fludrocortisone 125 12 12
Dexamethasone 0 26 17
HPA hypothalamic-pituitary-adrenal
(Adapted from Stewart [11])
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After the glucocorticoid withdrawal, the hypothalamic and
pituitary functions recover first, followed by the adrenocorti-
cal function. Full recovery of adrenal function can take
months, or even up to a year [13], especially after prolonged
steroid treatment with high doses. A possible scheme of
steroid discontinuation is presented in Table 3.
Corticosteroids and Pain Management
The process of pain origination is called nociception. It
consists of four stages: transduction (in peripheral nocicep-
tors), transmission (via neurons), modulation, and pain per-
ception. The possible role of steroids on every step of
nociception has been raised even though the exact mecha-
nisms remain unclear. The variety of proinflammatory cyto-
kines synthesized or/and released during tissue injury are
responsible for peripheral sensitization. This process leads
to an increase in pain perception. The reduction in inflam-
mation involved in this process decreases nociceptors acti-
vation, and thus, can diminish pain intensity. A decrease in
pathological electrical activity of damaged neurons is also
suggested [14]. The anti-inflammatory effect of glucocorti-
costeroids results from their ability to inhibit the expression
of collagenase (the key enzyme involved in tissue degener-
ation during inflammatory mechanisms), reduce pro-
inflammatory cytokines, and stimulate the synthesis of lip-
ocortin (blocks the production of eicosanoids) [15].
As a consequence, corticosteroids are considered to be
the most effective strategy against inflammatory pain. Ste-
roids also have an anti-swelling effect. The reduction of
peritumoral edema by the shrinkage of tumor in response
to steroid therapy may lead to the improvement in analgesia
in brain metastases [16] and spinal cord compression [17].
The modulation of neuroimmune interactions by corticoste-
roids and the decrease of spontaneous discharge in an in-
jured nerve may reduce neuropathic pain. The neurosteroids
produced in the central nervous system (CNS) or peripheral
nervous system (PNS) modulate the γ-aminobutyric acid
(GABA), NMDA, and P2X (for adenosine triphosphate or
biphosphate) receptors, which all play a crucial role in the
regulation of pain [18].
The receptors of various steroid hormones are expressed
in several neural structures, allowing steroids to control the
development, growth, maturation, differentiation, and plas-
ticity of the CNS and PNS. By modulating neural activity
and plasticity, the steroids are suspected to play an important
role in pain sensation. Sex steroids (androgens and estro-
gens) are key factors accounting for the gender difference in
pain and analgesia. Androgens, particularly testosterone,
exert an analgesic effect in humans while estrogens were
found to have both the hyperalgesic and analgesic effects,
depending on the experimental conditions [19, 20]. Sex
steroids in a rat model modulate the antinociceptive
responses to opioids through the control of κ- and δ-opioid
receptors in the spinal cord [21].
The most often prescribed corticosteroid for pain treatment
is dexamethasone. Long-acting dexamethasone causes less
fluid retention than other steroids because it has less mineral-
ocorticoid effect. However, betamethasone (equipotent to
dexamethasone), prednisone, and prednisolone also may be
used [22]. Dexamethasone is metabolized by the hepatic
enzyme CYP3A4 [23], and like other drugs metabolized in
this way, it has numerous potential interactions. It may affect
the metabolism of carbamazepine, tricyclic antidepressants,
venlafaxine, dextromethorphan, and, to less extent, metha-
done. The effect of dexamethasone may be increased by
CYP3A4 inhibitors and weakened by CYP3A4 inducers.
Corticosteroids are commonly prescribed in cancer patients
for a variety of symptoms [24, 25]. These include some
specific and non-specific indications. There is evidence for
the use of corticosteroids for specific indications such as
raised intracranial pressure, spinal cord compression, superior
vena cava obstruction, and bowel obstruction. However, there
has been little evidence for this in the literature with regard to
hypercalcemia and nonspecific indications such as pain, nau-
sea and vomiting, fatigue, cancer-induced anorexia-cachexia,
depressed mood, or poor general well-being and dyspnea [26].
The recommended dosing of corticosteroids in different clin-
ical situations is presented in Table 4.
Adverse Effects
Corticosteroids display short- and long-term toxicities. The
immediate adverse effects include immunosuppression,
which may manifest as candidosis, hyperglycemia, and psy-
chiatric disorders. Long-term effects comprise myopathy,
peptic ulceration, osteoporosis, and Cushing’s syndrome
[14]. Therefore, due to a wide range of adverse effects, the
lowest effective dose should be used. Additionally, other
medications to counteract steroid side effects can be
Table 3 The proposal schedule of glucocorticoid withdrawal when




Proposal schedule of tapering
≥ 7.5 mg Reduce rapidly, e.g. 2.5 mg every 3–4 days
then
5–7.5 mg Reduce by 1 mg every 2–4 weeks
then
< 5 mg Reduce by 1 mg every 2–4 weeks
(Adapted and modified from Livanou et al. [13])
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prescribed. The combination of NSAIDs and steroids
increases the risk of gastric bleeding 15-fold; therefore, it
should be avoided or gastroprotective drugs ought to be
administered concurrently [27]. Bisphosphonates should be
considered in the case of elderly patients and patients at risk
of osteoporosis, especially when chronic steroid therapy is
intended. Due to the diabetogenic effect of steroids, regular
measurements of glucose levels are needed in these patients
as well. All patients should be reviewed regularly to ensure
that the treatment benefits outweigh the risks [7].
In an uncontrolled study, oral candidosis and proximal
myopathy were the most frequent adverse effects attributable
to steroid therapy. The most common reason for discontinua-
tion of dexamethasone treatment was death or general deteri-
oration. A total of four (4 %) out of the 106 treated patients
discontinued the treatment due to adverse effects such as
restlessness, sleep disturbance, dyspepsia, and skin rash [24].
In another study, 181 (31 %) out of 582 cancer patients
experienced troublesome adverse effects. The most common
adverse effects were moon face (43 %), myopathy/muscle
weakness (34 %), skin purpura (31 %), oral candidosis
(28 %), and aggravated or triggered diabetes mellitus (17 %)
[22]. Among 88 patients with brain metastases, the most
frequently documented adverse effects of steroids were in-
creased appetite (32 %), proximal muscle weakness (28 %),
and insomnia (21 %). Only 25 % of treated patients did not
experience steroid-induced adverse effects [28].
A comparison of prednisolone with dexamethasone
showed that adverse effects of both drugs were similar,
although more psychological changes (P<0.02) and hyper-
activity (P<0.05) were observed in patients treated with
dexamethasone [29]. When comparing betamethasone with
prednisolone, 33 % and 20 % of cancer patients, respective-
ly, were assessed as having troublesome adverse effects.
Gastroprotectors were prescribed by 27 % of doctors to
75–100 % of their patients treated with corticosteroids, and
65 % of physicians prescribed these drugs when patients
received corticosteroids and NSAIDs concurrently [22]. Al-
though hiccup is not a very frequent adverse effect of
dexamethasone, in a recent case series, Kang et al. [30•]
presented dexamethasone-induced hiccup that was easily
resolved by switching to an equipotent dosage of either
prednisolone or methylprednisolone.
Dexamethasone is often administered subcutaneously. It
is alkaline, so it is highly likely to be incompatible with
acidic solutions. If dexamethasone is to be mixed with other
drugs, as much diluents as possible should be added before
the addition of dexamethasone. Dexamethasone is incom-
patible in mixtures with haloperidol, midazolam, prometha-
zine, and levomepromazine. Glycopyrronium chemically
interacts with dexamethasone, but no precipitate forms;
therefore, this combination should be avoided. Dexametha-
sone is compatible in mixtures with morphine, diamorphine,
oxycodone, fentanyl, alfentanil, hydromorphone, dihydro-
codeine, tramadol, hyoscine butylbromide, hyoscine hydro-
bromide, metoclopramide, and ondansetron [31].
Overview of Clinical Studies of Corticosteroids
in Cancer Patients
There is little recent evidence for the effectiveness and
toxicity of corticosteroids in cancer. Some uncontrolled
studies reported benefits of corticosteroids on pain and
symptom control in these patients. The issue of an appro-
priate steroid treatment is discussed in the literature, and
many questions regarding this problem have been raised
(What are the exact indications for corticosteroid use? When
should the steroid treatment be started? How long are ste-
roids effective in symptom management, including pain?
What is the most effective steroid dose? What are the most
common adverse effects in cancer patients? Do we prescribe
steroids too often in palliative care?). The studies presented
below attempted to answer these important queries.
Nauck et al. [32], in a multicenter study carried out in 55
palliative care units in Germany and one in Austria and
Switzerland, established that corticosteroids were one of
the commonly administered drugs and were administered
to 33 % of those patients. Corticosteroids were prescribed to
17.8 % of patients on admission and 32.4 % of patients
during the stay at inpatient units. Younger patients were
treated more often with corticosteroids [32]. In a more
recent study conducted among 406 patients with advanced
cancer who were consulted by a palliative care team in an
outpatient clinic, corticosteroids were administered to about
25 % of patients [33]. A retrospective observation of corti-
costeroid use at the end of life in hospice patients conducted
Table 4 Corticosteroid doses for common indications in cancer
patients




8–16 mg dexamethasone daily
Spinal cord
compression
16–32 mg dexamethasone daily (8–16 mg b.i.d.)
Superior vena cava
obstruction
16–24 mg dexamethasone daily (8 mg b.i.d or
t.i.d.)
Bowel obstruction 8–16 mg dexamethasone daily
Nonspecific
Anorexia 4 mg dexamethasone; 10–20 mg prednisolone




(Adapted and modified from Exton [26])
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by Gannon et al. [25] revealed and confirmed high preva-
lence of corticoid use. A total of 51 % of 178 patients
received corticosteroids, which were continued until death
in 53 %. Only 2 % were switched from oral to parenteral
corticosteroids. The main indications included treatment for
raised intracranial pressure and to give a “boost.” The fore-
most reason for discontinuation of steroids was loss of the
oral route.
According to the previously presented data, corticoste-
roids were suspected to improve pain control. Bruera et al.
[34] conducted a randomized, double-blind, crossover study
in 40 patients with advanced cancer. Oral methylpredniso-
lone, 16 mg twice daily, or placebo was administered for
5 days. Then the patients were crossed over to the alternate
treatment after 3 days of washout period. All the patients
were then given methylprednisolone for 20 days. A total of
28 patients had pain of either bone, visceral, or neuropathic
origin. Visual analogue scale scores for pain and analgesic
intake were lower in the case of the methylprednisolone
treatment in all types of pain. The benefit disappeared after
day 33 in one third of the patients.
In a Swedish survey, out of a total of 147 patients with pain,
50 (34 %) had very good effect, 71 (48 %) had some effect, 4
(3 %) had no effect, and the effect of the treatment with
corticosteroids could not be assessed in 22 patients (15 %).
The positive response came within a week and lasted for more
than 4 weeks. Of these patients, 81 % used corticosteroids for
more than 4 weeks and 90 % were on betamethasone, with
daily doses less than 3 mg in most of the patients [22].
Della Cuna et al. [35] reported a randomized double-
blind study conducted among 43 patients with advanced
cancer who were given either methylprednisolone, 125 mg
intravenously daily, or placebo for 8 weeks. Visual analogue
scale scores for pain improved in the methylprednisolone-
treated group. However, the follow-up study conducted
among 173 women did not confirm analgesic effects of
methylprednisolone [36]. Tannock et al. [37] reported an
uncontrolled study of oral prednisone, 7.5–10 mg daily, in
37 patients with metastatic prostate cancer. Bone pain was
relieved in 14 patients. The response appeared to correlate
with a decreased level of androgens [37].
Greenberg et al. [38] reported an uncontrolled study of 83
patients with spinal cord compression and pain who re-
ceived dexamethasone, 100 mg intravenously, followed by
24 mg orally four times daily tapered over the period of
2 weeks. The patients were treated concurrently with radio-
therapy. Pain relief was observed in 82 % of patients, in
some patients before the commencement of radiotherapy. In
an uncontrolled study, Kozin et al. [39] demonstrated pain
relief in 63 % of 64 patients with reflex sympathetic dystro-
phy. The initial dose of dexamethasone was 60–80 mg daily
with subsequent taper. Positive scintigraphy predicted a
positive response to the treatment.
Sturdza et al. [28] reported the use of steroids among
oncologists and palliative care physicians in the management
of patients with brain metastases. Out of 38 physicians
approached, 34 responded to this electronic survey; 45 %
routinely used dexamethasone, 4 mg four times daily (16 mg
daily). The others determined the dose of steroid according to
the presence or absence of neurological symptoms. The dose
was tapered over 4 weeks following completion of the whole
brain radiotherapy by 60 % of the physicians.
Hanks et al. [29] observed that dexamethasone showed
tendency for better results than prednisolone in patients with
pain due to compression of the nerve. A total of 16 out of 34
patients responded to the treatment: 8 (38 %) out of 21
patients treated with prednisolone and 8 (62 %) out of 13
patients treated with dexamethasone. However, this trend
could have been associated with relatively higher doses of
dexamethasone (4 mg daily, n07; 8 mg, n04, 16 mg, n02)
compared with the doses of prednisolone (30 mg daily, n0
10; 20 mg or less, n011) [29].
Several case reports demonstrated the effectiveness of
corticosteroids in bone pain treatment. Arkel et al. [40]
demonstrated effective use of corticosteroids in intractable
bone pain in the course of hairy cell leukemia [40]. Vyvey
[41•] depicted a patient with a pancreatic carcinoid with
metastases to the liver and spine and mixed bone and neu-
ropathic pain. The patient suffered from moderate pain
despite hydromorphone administration. The patient was
successfully treated with dexamethasone, 8 mg per day
orally, which was subsequently reduced after a few days to
the dose of 4 mg per day orally for 3 months.
Corticosteroids are commonly used for quality of life and
symptom control improvement. Hardy et al. [24] conducted
an uncontrolled study among 106 consecutive patients who
started dexamethasone treatment according to the estab-
lished prescription policy. The patients were surveyed each
week to document the indications for use, beneficial effects,
toxicity incurred and the reason for discontinuation of the
treatment. All patients were diagnosed with advanced can-
cer and the median survival time was 40.5 days (range: 1–
398 days) from the start of dexamethasone treatment. Three
or more assessments were completed by 57 % of patients.
The most common specific indications for treatment with
dexamethasone were spinal cord compression, cerebral me-
tastases, lymphangitis carcinomatosa, and bowel obstruc-
tion. The most common nonspecific indications comprised
anorexia, nausea, low mood, pain, and vomiting. The medi-
an duration of steroid use was 21.5 days (range: 1–89 days).
Symptom scores improved during the therapy compared
with baseline in most patients for anorexia, nausea, pain,
low mood, vomiting, and weakness, but not with respect to
dyspnea and poor mobility.
Beneficial effects of steroid use on appetite, vomit-
ing, general well-being, and social interaction in the
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Dellacuna et al. [33] study were noticed. In doctors’
assessment, the positive effect of steroids was seen by
71 % of physicians in poor well-being, 53 % in appetite
loss, 45 % in nausea, and 40 % in fatigue. Moertel et
al. [42] reported a significant improvement in appetite
in a randomized, double-blind, placebo-controlled study
of dexamethasone in 116 patients with advanced gastro-
intestinal cancer after 4 weeks, although weight did not
increase. Improvements in depression, appetite, and food
consumption also were observed. Strength was insignif-
icantly improved, and performance status and survival
were not different form control.
The problem of appropriate steroid dose and its effi-
cacy is raised in the literature and clinical practice. In a
randomized double-blind trial Vecht et al. [43] com-
pared initial dexamethasone dose of 10 mg versus
100 mg in 37 patients with spinal cord compression
who then received radiotherapy. No significant differ-
ences were found between the patient groups with re-
spect to pain relief.
Lundström and Fürst [22] asserted that betamethasone
(equipotent to dexamethasone) was the most commonly
prescribed drug followed by prednisolone. Dexamethasone
was used only by a few physicians. The dose for the treat-
ment of anorexia, fatigue, or low mood was betamethasone,
3.5 mg, or prednisolone, 17 mg. The mean starting doses for
the treatment of nausea were 4.8 mg and 19 mg, respective-
ly. The dose was tapered to maintenance dose if possible by
75 % of physicians; 83 % stated that more than 50 % of their
patients had a positive effect of the treatment, and 97 % of
the respondents stated that the positive effect came within
5 days.
Hanks et al. [29] reported an uncontrolled study
examining the effects of prednisolone or dexamethasone
in 218 (58 %) of a total 373 patients with advanced
cancer admitted to the inpatient unit. The duration of
treatment with corticosteroids varied from 1 day to
almost 11 years; the median duration was between 4
and 8 weeks. Patients received either prednisolone (n0
121) or dexamethasone (n095) in starting doses of 10–
30 mg and 4–16 mg daily, respectively. The mainte-
nance daily doses varied considerably from 5–20 mg of
prednisolone and from 0.5 mg on alternate days to
4 mg twice daily of dexamethasone. There was no
difference in response rates between the two drugs.
The beginning and duration time of the clinical effect
of corticosteroids is another unclear problem. In the
Swedish study, the authors noted that positive effect of
steroids lasted from 3 to 6 weeks. Of the questioned
doctors, 83 % stated that more than 50 % of their
patients had a positive effect from the treatment, and
97 % of the respondents observed the positive effect
within 5 days [22].
Conclusions
Corticosteroids have an established role in specific indications
in cancer patients such as spinal cord compression, superior
vena cava syndrome, brain metastases with raised intracranial
pressure and bowel obstruction. Their role in non-specific
indications is not well proved. Clinical practice and several
studies suggest that corticosteroids may be effective in the
treatment of bone and neuropathic pain, when administered
along with opioids and with other adjuvant analgesics. The
decrease in pain intensity is probably connected with both the
anti-inflammatory and anti-swelling effects as well as modu-
lation of neuroimmune interactions. The sex-steroid depen-
dent differences in pain sensitivity were also found.
It seems that dexamethasone may be commonly used for
cancer pain management due to its high potency, long du-
ration of action and minimal mineralocorticoid effect. A
proposed starting daily dose is 8 mg (orally, subcutaneously
or intravenously) with subsequent adjustment to the analge-
sia achieved and adverse effects. The lowest effective dose
should be used and patients must be followed up regularly to
assess benefits and risks associated with the therapy. In the
situation when the general condition of a patient deteriorates
and the patient is no longer able to swallow medications that
are taken orally, it is rather recommended not to stop the
treatment abruptly but to continue dexamethasone adminis-
tration by the subcutaneous route.
Patients with severe pain intensity of bone and neuro-
pathic origin should also be considered for the use of anal-
gesic ladder step 3 opioids (opioids for moderate to severe
pain, strong opioids) without climbing up the analgesic
ladder. Other co-analgesics appropriate for bone and neuro-
pathic pain should also be considered. Future studies that
would take patients’ quality of life into consideration and
could establish the role of corticosteroids in pain and other
symptom treatment, are urgently needed.
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